Exploring how different dengue virus lineages affect outbreak risks
Official title: Understanding the Impact of Dengue Virus Lineage Persistence on Outbreak Potential
Funded at Yale University · NIH-10995563 · Data updated 2026-11-12
This study is looking at the different types of the dengue virus to see how they change and cause outbreaks, which can help us find better ways to prevent and control dengue in the future.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $48,974 |
| NIH project number | 1F31AI186435-01 |
| Project ID | NIH-10995563 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living in regions where dengue is endemic or where outbreaks have occurred.
✕Less likely to help
Patients who do not reside in dengue-affected areas or who have no history of dengue infection may not benefit from this research.
What this research studies
This research investigates the genetic diversity and evolution of the dengue virus to better understand how certain lineages contribute to outbreaks. By analyzing the virus's genomic data, the study aims to identify which lineages have been responsible for past outbreaks and the factors that influence their persistence over time. The approach includes detailed phylogenetic analysis, integrating lessons learned from the COVID-19 pandemic and other viral outbreaks. This research could lead to improved public health strategies for dengue prevention and control.
Why it matters
Potential benefit: If successful, this research could enhance our ability to predict and manage dengue outbreaks, ultimately reducing the disease's impact on affected populations.
How similar studies have gone: Previous research on viral genomics has shown promise in improving outbreak forecasting and control measures for other viruses, suggesting potential success for this approach with dengue.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Porzucek, Abbey — Yale University
- Study coordinator: Porzucek, Abbey
Related research
Other NIH-funded projects on the same topics.
-
Immune responses linked to severe dengue in children (primary infection)
This grant studies why some kids get very sick from their first dengue infection and how their immune system reacts differently from secondary infections.
-
Phase 2b trial of dengue vaccines TAK-003 and Butantan-DV to boost lasting, broad antibody protection
A trial tests whether giving a second dengue vaccine (Butantan-DV) after an initial TAK-003 shot can create stronger, longer-lasting antibodies that work against all dengue types.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Selective GAK inhibitors to fight dengue, VEEV and other emerging viral infections
A Stanford team is testing new, selective inhibitors of GAK to block how certain viruses enter and exit cells, with the goal of a broad antiviral approach that could help people exposed to dengue, VEEV, and similar infections.
-
Defining immune markers predicting protection against dengue in a long-term family study in Thailand
This grant looks at how antibodies develop to protect against dengue in children from a long-running family cohort in Thailand, with the goal of identifying immune signs that predict protection across multiple dengue serotypes.
-
Understanding dengue protection in children from a long-term Thai family cohort
A long-term study in Thailand follows families to understand how early exposures to dengue shape protection and illness risk for children as they encounter the virus over time.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.